Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Research analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Monday, March 24th. William Blair analyst M.

NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic ...

Virtual Meeting to be held on March 18 hosted by Piper Sandler. Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

As of March 19, 2025, the average one-year price target for Immunic is $13.43/share. The forecasts range from a low of $5.05 to a high of $29.40. The average price target represents an increase of ...